A multicentre study to assess prognostic performance and optimal timing for sampling within the peri- and post-discharge period of recently discovered promising Heart Failure biomarkers for indication of 30, 90, 180 days and 1 year prognosis.

niversity of Otago, Christchurch0 个研究点目标入组 450 人开始时间: 2015年1月21日最近更新: 2021年11月1日

适应症

试验速览

暂无简介。

•1.Patients aged >18 year,
•2.Admitted with ADHF as evidenced by typical clinical features plus either radiological evidence of HF or an NTproBNP level >1000pg/ml (120 pmol/L).

•1.A primary diagnosis of either acute coronary syndrome (ACS), myocarditis/pericarditis, pericardial constriction or AF with rapid ventricular rate
•2.Severe valvular disease requiring surgery, severe aortic stenosis (valve area <1 cm^2), or HF due to mitral stenosis
•3.Under consideration for cardiac transplantation
•4.Currently enrolled in other interventional or therapeutic heart failure trial.
•5.Life expectancy due to non-cardiac disease of <6 months
•6.Concurrent severe hepatic disease (determined by investigator)
•7.Concurrent severe pulmonary disease (FEV1<1 L)
•8.Severe renal impairment (plasma creatinine >250 micromol/L, EGFR < 15mls/min) or receiving renal replacement therapy.
•9.Unwilling or unable to consent
•10.Unable to comply with study protocol (e.g. out of town)
•11.Pregnant, nursing or planning to be pregnant.
•12.Is already enrolled in this study.

发起方

niversity of Otago, Christchurch